Cardiolipin membrane binding
SS-31 associates with cardiolipin, a negatively charged phospholipid concentrated in the inner mitochondrial membrane. Cardiolipin helps organize membrane shape and respiratory proteins.

Compound guide
A pathway-focused guide to molecular mechanisms, published evidence, and the limits of interpretation.
Overview
SS-31, also called elamipretide, is a short mitochondria-targeting tetrapeptide studied for its interaction with cardiolipin in the inner mitochondrial membrane.
Its cardiolipin interactions are investigated for effects on membrane organization, respiratory-chain efficiency, ATP production, and oxidative-stress responses.
SS-31 has substantial preclinical literature and has entered clinical trials in selected disorders, but findings are indication-specific and do not establish a general consumer benefit.
Research model
These receptors, enzymes, and signaling networks define the primary laboratory questions associated with this research material.
SS-31 associates with cardiolipin, a negatively charged phospholipid concentrated in the inner mitochondrial membrane. Cardiolipin helps organize membrane shape and respiratory proteins.
Preclinical work suggests cardiolipin interactions can support cristae structure and the arrangement of electron-transport proteins, including the relationship between cardiolipin and cytochrome c.
By influencing membrane and electron-transport behavior, SS-31 is proposed to reduce excessive reactive-oxygen-species formation and downstream oxidative damage in stressed cells.
Research interpretation
SS-31 associates with cardiolipin, a negatively charged phospholipid concentrated in the inner mitochondrial membrane.
Preclinical work suggests cardiolipin interactions can support cristae structure and the arrangement of electron-transport proteins, including the relationship between cardiolipin and cytochrome c.
By influencing membrane and electron-transport behavior, SS-31 is proposed to reduce excessive reactive-oxygen-species formation and downstream oxidative damage in stressed cells.
SS-31 has substantial preclinical literature and has entered clinical trials in selected disorders, but findings are indication-specific and do not establish a general consumer benefit.
Read the evidence
One important note
SS-31 has been tested in human mitochondrial-disease trials. Early studies reported selected signals, while the larger MMPOWER-3 trial did not improve its primary walking-distance or fatigue endpoints.
This guide summarizes molecular mechanisms, published evidence, and evidence limits in everyday language. It is educational information, not medical advice or instructions for personal use. Products offered on this site are intended exclusively for laboratory research and are not for human or veterinary use.